Smith Christian Adam
Known title: Chief Commercial OfficerCIK: 0002072266
Smith Christian Adam's purchase track record
Smith Christian Adam has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/11/2026 | MMSI | $99K | +48.8% | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| MMSI | ▲ Buy | Open Market | 1,626 | $99K | 5/11/2026 | View on chart |
| MMSI | ▲ Buy | Grant | 8,203 | $0 | 2/26/2026 | View on chart |
| MMSI | ▼ Sell | Tax Withholding | 2,018 | $157K | 2/26/2026 | View on chart |
| MMSI | ▲ Buy | Grant | 6,409 | $0 | 2/26/2026 | View on chart |
| MMSI | ▲ Buy | Grant | 6,762 | $0 | 2/26/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Merit Medical Systems sets Q3 2026 earnings date
Merit Medical Systems announced it will report its third-quarter 2026 results on October 29, 2026. This upcoming earnings date is the primary catalyst for the stock, as investors await fresh financial updates. The company is currently trading within its 52-week range, with an average analyst target price of $101.45.
Merit Medical Systems sets Q3 2026 earnings date. Merit Medical Systems announced it will report its third-quarter 2026 results on October 29, 2026. This upcoming earnings date is the primary catalyst for the stock, as investors await fresh financial updates. The company is currently trading within its 52-week range, with an average analyst target price of $101.45.